These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 37745904)
1. Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials. Lee YS; Kim SH; Tae JH; Chang IH; Kim TH; Myung SC; Kim M; Nguyen TT; Choi J; Kim JH; Kim JW; Choi SY Prostate Int; 2023 Sep; 11(3):159-166. PubMed ID: 37745904 [TBL] [Abstract][Full Text] [Related]
2. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809 [TBL] [Abstract][Full Text] [Related]
3. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer]. Wenzel M; Hoeh B; Chun FKH; Mandel P Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112 [TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
6. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323 [TBL] [Abstract][Full Text] [Related]
7. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy for high-volume Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773 [No Abstract] [Full Text] [Related]
9. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976 [TBL] [Abstract][Full Text] [Related]
10. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Jian T; Zhan Y; Hu K; He L; Chen S; Hu R; Lu J Front Pharmacol; 2022; 13():955925. PubMed ID: 36278154 [No Abstract] [Full Text] [Related]
11. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754 [TBL] [Abstract][Full Text] [Related]
12. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225 [TBL] [Abstract][Full Text] [Related]
13. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293 [TBL] [Abstract][Full Text] [Related]
14. Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Wang L; Li C; Zhao Z; Li X; Tang C; Guan Z; Sun F; Gu J; Li N Front Oncol; 2023; 13():1104242. PubMed ID: 36959793 [TBL] [Abstract][Full Text] [Related]
15. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer]. Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. Chen J; Ni Y; Sun G; Liao B; Zhang X; Zhao J; Zhu S; Wang Z; Shen P; Zeng H Front Oncol; 2020; 10():519388. PubMed ID: 33072564 [No Abstract] [Full Text] [Related]
17. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173 [TBL] [Abstract][Full Text] [Related]
18. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970 [TBL] [Abstract][Full Text] [Related]
19. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Mutlu H; Bozcuk H J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915 [TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Kassem L; Shohdy KS; Abdel-Rahman O Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]